25.34 — The Software Engineer Inside a GxP World

Your first regulated project will feel slow for reasons that are not obvious. The build is not the slow part. Waiting for a signature is. Discovering in week nine that the report you wrote is used to release product, and therefore needed validating, is. Learning that the vendor pushed a platform update over the weekend and somebody now has to assess whether the system is still in its validated state is.

None of that is unpredictable once you know the shape of the environment. This chapter is that shape: where the systems sit, what you will actually be asked to produce, how to estimate it, the traps, and — since your company needs a continuing flow of work rather than one project — where the next engagement reliably comes from.

The value chain, and where the systems sit

Lay the whole industry out as a chain and every system in it has a place. This is the map to have in your head when a client mentions a system by name.

Stage	Systems	Regulated?
Discovery	Notebooks, compound and screening data	Rarely GxP, IP-sensitive
Preclinical	Study management, toxicology data	GLP
Clinical	EDC, CTMS, eTMF, IRT, eCOA	GCP
Safety	Safety database, signal tools	GVP
Manufacturing	MES, LIMS, historians, ERP	GMP
Distribution	Serialisation, warehouse, cold chain	GDP
Regulatory	RIM, publishing, submission gateways	Regulated records
Quality	Deviations, CAPA, change, training	GxP core
Commercial	CRM, medical affairs, patient programs	Privacy, compliance
Payer / provider	Claims, coding, EHR, interoperability	HIPAA, CMS rules

Two observations from that table are worth more than the table itself.

The regulatory weight is not evenly distributed. Discovery is nearly unregulated; quality and manufacturing are the heaviest. A services company can move fast in some rows and must move carefully in others, and pricing work as though every row is the same is how engagements lose money.

And the failure of a system in any row eventually reaches a patient. That is the sentence to keep when the process feels excessive.

What you will actually be asked to produce

Beyond working software, a regulated project produces a documentation set. Chapter 25.21 explained why each item exists; here is what it means for your week.

Requirements you can be held to. Numbered, testable, approved before build. If your client uses a backlog rather than a document, that is fine, provided items are identified, versioned and approved — but somebody must have signed something before you started.

Design documentation proportionate to what you built: an architecture description, configuration specifications, and for custom code a design that explains the parts that carry risk.

Test evidence. Executed protocols with dated signatures, or automated results tied to a build. Any test that failed and was fixed is recorded as such — a test suite that shows only passes on the first run is not believable, and inspectors know it.

A traceability matrix, which your tooling should generate rather than a person maintain.

Procedures and training. The system is not usable until the people using it have a procedure and are trained on it, with records. This is routinely left out of project plans and is routinely the reason go-live slips.

And the operational artefacts nobody budgets for: access review procedures, backup and restore tests, disaster recovery evidence, the audit trail review process, periodic review scheduling, and an archiving plan for the day the system is retired.

Estimating, realistically

The single most useful number to internalise is that in a fully regulated system, the effort around the software is comparable to the effort of the software itself, and sometimes larger.

Where that time goes. Writing and approving specifications. Writing and executing test protocols. Review cycles, each of which has a queue. Signature latency — the approver is on holiday and there is no delegate configured. Change control on anything already validated. Training delivery. And the final release package.

Three practical rules follow.

Front-load the agreements. Get the validation approach, the risk classification and the deliverable list agreed in writing in week one. Arguing about how much testing is enough at the end of a project is the most expensive conversation available.

Plan approvals as dependencies with names attached, because they behave exactly like external dependencies and are usually tracked as though they are free.

And keep a small non-GxP corner of the programme — a reporting layer, a prototype, an internal tool — where you can move fast and demonstrate value while the regulated part proceeds at its proper pace.

The traps

These are the specific things that catch engineers arriving from ordinary technology work. Every one of them has cost somebody a rework cycle.

Hard deletes. A regulated system does not remove records. Design for soft deletion with reason and signature from day one; retrofitting it means migrating history you no longer have.

Client-supplied timestamps. Time must come from a controlled source. A record timestamped by a user's browser cannot support attribution.

Shared service accounts. A background job writing records as "system" is acceptable if it is genuinely automatic. A human using a shared account is not, ever.

"It is just a report." If a human uses the output to make a GxP decision — release a batch, close a deviation, submit a report — the report is part of the regulated system and its calculation must be verified.

Vendor updates to software-as-a-service. The vendor's continuous release cycle can move faster than your client's ability to assess changes. The answer is a defined process: release notes reviewed against a risk assessment, a regression suite that runs automatically, and a documented conclusion. Get that agreed with the vendor before signing anything.

Patching. Security wants patches immediately; validation wants assessment first. The resolution is a pre-agreed, risk-based patch policy, not an argument per patch.

Test data. Never production data (Chapter 25.33). Synthetic data that exercises the awkward cases is a deliverable worth building properly once and reusing.

Spreadsheets. The most common unvalidated regulated system in existence. When you find one performing a calculation that matters, you have found both a compliance problem and a project.

And model-based features. Anything where the output cannot be explained needs a human decision point, recorded, plus monitoring and a defined path for retraining. Chapters 25.16 and 25.22 give the boundaries in device and safety contexts.

Working with the people who can stop you

Three roles hold veto power over your work, and each is persuaded differently.

Quality assurance cares whether the evidence will survive an inspection. Bring them in at design, ask what evidence they will need, and build it as a feature. A QA lead who was consulted early is an ally; one who first sees the system at validation is an obstacle, and correctly so.

Regulatory affairs cares whether anything you built changes what was filed with an agency (Chapter 25.24). Ask early whether the process you are touching is described in a submission.

And the business process owner or subject matter expert cares whether the system matches how the work is really done. They know the workarounds, and the workarounds are the requirements nobody wrote down.

The general rule: in this industry, agreement is cheap before the build and expensive after it.

Where the next project comes from

A services company needs a pipeline, not a project. The reliable sources are these, in rough order of how easy they are to sell.

The regulatory calendar. Every deadline in this Part is a programme somebody must fund, with a date they cannot move. Currently visible examples: the final phase of American drug supply chain serialisation for the smallest dispensers on 27 November 2026; the payer interoperability and prior authorisation interfaces due 1 January 2027; the European device regulation transition dates of 31 December 2027 and 31 December 2028; the European computerised systems annex revision and its new artificial intelligence annex working through to adoption; and the proposed American security rule update now expected in 2027. Maintaining that calendar as a live document, mapped to each client's exposure, is the cheapest business development activity available and almost nobody does it.

Manual transcription between systems. Wherever a person reads a number from one screen and types it into another, there is a project with a quantifiable error rate attached.

Reconciliation. Between a safety database and a clinical database, between a plan's encounter data and its claims, between a hub's records and a pharmacy's — these run monthly, manually, forever.

The metrics gap. From Chapter 25.17: the numbers a client reports upward are usually assembled by hand from data that already exists in systems. Automating a monthly quality review pack is small, visible and leads to larger work.

Inspection readiness. Retrieval speed, completeness, traceability. Sell it before an inspection, not during one.

Migrations forced by end-of-life. A validated system whose vendor is ending support must be replaced, with its records preserved and readable.

And the honest efficiency case. Same or better evidence, fewer human hours (Chapter 25.1). Every proposal should be able to state it in that form in one sentence.

How to build things worth reusing

The difference between a services company that grows and one that runs a series of unrelated projects is what it keeps between engagements.

Validation accelerators — templates, standard test approaches, traceability tooling, and a documented method that a client's quality group has already accepted once. The second client's validation costs a fraction of the first's, and that margin is the business.

Qualified components. An audit trail service, an electronic signature component, a reporting layer that meets the requirements of Chapter 25.20. Build them once, properly, with their evidence package.

Reference data and terminology assets for the healthcare side, where the code mappings from Chapter 25.31 are expensive to build and stable across clients.

And synthetic data sets shaped like real clinical, safety or claims data, which every project needs and every project rebuilds.

What to read, and what to learn

Staying current here is unusually easy because the regulators publish everything.

Read the agency guidance documents in your area — they are written to be read, and they answer the questions clients argue about. Read published inspection findings and warning letters; they tell you what actually goes wrong. Read the implementation guides for whatever standard you are working with, rather than a vendor's summary of them. And read a client's own published history before a proposal.

The recognised bodies worth knowing by name, because their frameworks come up constantly: ISPE, which publishes the good practice guides including the one at the centre of Chapter 25.21; RAPS for regulatory affairs; ACRP and SOCRA for clinical research; AAMI for devices; HIMSS for health IT; and the coding credentialing bodies for revenue cycle work.

One last piece of advice about how to be regarded here. Domain credibility in this industry comes from accuracy, not fluency. Knowing that the review clock starts at filing rather than submission, that "addressable" does not mean optional, that a Form 483 is not a warning letter, and that severity and seriousness are different words — these small precisions are what make a client believe you understand their world. They are also, conveniently, all in this Part.

Next: Chapter 25.35, every role in this industry — what they do, what qualification they hold, and what they need from you.